















































# Supplementary Table 1. Plasma biomarkers of infection and immune activation



Pro-inflammatory cytokines	
Biomarker	Clinical significance in malaria infection
CRP	  In Ugandan children with <i>falciparum</i> cerebral malaria, plasma levels were significantly higher in retinopathy-positive patients compared with retinopathy-negative cases (1).
	   Whole blood and plasma concentrations were significantly elevated in malaria-infected patients from Malaysia and Indonesian Papua, compared with healthy controls. Patients were mono-infected with <i>Plasmodium falciparum</i> , <i>vivax</i> , <i>knowlesi</i> , <i>malariae</i> or <i>ovale</i> as confirmed by PCR (2).
	  In Cambodian asymptomatic participants, plasma levels were significantly higher in parasitaemic individuals compared with uninfected, age-, sex-, and village-matched controls. Patients had either a <i>falciparum</i> or <i>vivax</i> mono-infection, a <i>Plasmodium</i> infection with indeterminate species, or a mixed infection (3).
	  In Brazilian patients with <i>falciparum</i> or <i>vivax</i> malaria, plasma levels were significantly higher in infected individuals compared with healthy controls. Levels were also higher in <i>vivax</i> patients than in <i>falciparum</i> cases (4).
GM-CSF	To the best of our knowledge, no studies have reported significant group differences in the context of human malaria.
IFN- $\gamma$	  Plasma levels were significantly higher in Rwandan patients with severe malaria, compared with uncomplicated cases and controls (5).
	 Plasma levels were significantly higher in Colombian patients with <i>vivax</i> severe malaria, compared with uncomplicated cases and healthy controls (6).
	 In Brazilian patients with different forms of <i>vivax</i> malaria and controls, a network analysis revealed that IFN- $\gamma$ , TNF- $\alpha$ , and CCL5 were crucial in the profile of mild malaria cases (7).
IL-1 $\alpha$	To the best of our knowledge, no studies have reported significant group differences in the context of human malaria.
IL-1 $\beta$ *	   A meta-analysis revealed that IL-1 $\beta$ blood levels were higher in severe malaria patients compared with uncomplicated cases. <i>Plasmodium spp.</i> was a confounder in the meta-analysis, showing no difference in IL-1 $\beta$ levels between <i>falciparum</i> -infected groups (8).
	 In Indian patients with <i>falciparum</i> malaria, IL-1 $\beta$ levels were significantly the highest in severe cases with no brain injury, compared with other groups (9).
	 In Beninese children with <i>falciparum</i> cerebral malaria, plasma levels were significantly higher in fatal cases compared with those who survived (10).
IL-2	 Compared with Mozambican adults with life-long exposure to <i>falciparum</i> malaria, Spanish travellers diagnosed with malaria had significantly higher serum IL-2 levels (11,12).
IL-6*	  Plasma levels were significantly higher in Rwandan patients with severe malaria, compared with uncomplicated cases and controls (5).
	 Plasma IL-6 levels were significantly higher in Colombian patients with <i>vivax</i> severe malaria, compared with uncomplicated cases and healthy controls (6).
	 Plasma levels were increased in Brazilian patients with <i>vivax</i> malaria, compared with non-infected subjects with previous malaria episodes. Infected patients showed a strong correlation between CCL2 and IL-6 plasma levels, and moderate correlations between IL-6 and IL-10 (13).
	 In Pakistani patients with <i>vivax</i> malaria, plasma levels were significantly higher in uncomplicated cases than healthy controls, and in complicated cases than in uncomplicated ones (14).
IL-8	 In Beninese children with <i>falciparum</i> cerebral malaria, plasma levels were significantly higher in fatal cases compared with those who survived. In the former, IL-8 was identified as a risk factor for death by multivariate analysis (10).
IL-17A	 Plasma levels were significantly higher in Ghanian children with severe <i>falciparum</i> malaria, compared with uncomplicated cases and non-malaria febrile controls (15).
	 In Indian patients with <i>falciparum</i> malaria, plasma levels were higher in patients with multi-organ dysfunction compared with other severe malaria subgroups, suggesting IL-17 plays a role in renal inflammatory pathology during <i>falciparum</i> infection (16).

		Plasma levels were significantly higher in Rwandan patients with severe malaria, compared with uncomplicated cases and controls (5).
		Plasma levels were significantly higher in Brazilian patients with <i>vivax</i> malaria, compared with previously exposed, non-infected subjects and unexposed healthy donors (13).
<b>MIF</b>		Host MIF plasma concentrations positively correlated with <i>vivax</i> MIF levels in the plasma of Chinese patients with uncomplicated malaria (17).
<b>MPO</b>		In Cameroonian participants, plasma MPO levels were significantly higher in patients with <i>falciparum</i> malaria when compared with negative controls (18).
<b>TNF-<math>\alpha</math></b>		Serum levels were significantly higher in Indian patients with <i>falciparum</i> severe malaria and cerebral malaria, compared with healthy controls (19).
		In Beninese children with <i>falciparum</i> cerebral malaria, plasma levels were significantly higher in fatal cases compared with those who survived (10).
		TNF- $\alpha$ -producing monocytes were significantly lower in Malawian children with <i>falciparum</i> malaria compared with healthy controls. Cerebral malaria cases had the lowest values (20).
		Plasma levels were significantly higher in Rwandan patients with severe malaria, compared with uncomplicated cases and controls (5).
		In Brazilian patients with different forms of <i>vivax</i> malaria and controls, a network analysis revealed that IFN- $\gamma$ , TNF- $\alpha$ , and CCL5 were crucial in the profile of mild malaria cases (7).
		In Pakistani patients with <i>vivax</i> malaria, plasma levels were significantly higher in complicated cases compared with uncomplicated ones. TNF- $\alpha$ , IL-10, ICAM-1 and VCAM-1 were the best individual predictors of complicated <i>vivax</i> malaria (14).





### Anti-inflammatory cytokines

Biomarker	Clinical significance in malaria infection
<b>IL-1RA</b>	 Most abundant cytokine measured in the serum of Malaysian Borneo patients with <i>falciparum</i> , <i>vivax</i> , or <i>knowlesi</i> malaria. Serum levels correlated with parasitaemia in subjects infected with any of the parasite species, and was associated with complications in <i>knowlesi</i> -infected patients (21).
<b>IL-4**</b>	 Plasma levels were significantly higher in Colombian patients with <i>vivax</i> severe malaria, compared with uncomplicated cases and healthy controls (6).
	 In Brazilian patients with different forms of <i>vivax</i> malaria and controls, a network analysis revealed a protective role of IL-4 and IL-10 in non-infected and asymptomatic patients (7).
<b>IL-10</b>	 In Beninese children with <i>falciparum</i> cerebral malaria, plasma levels were significantly higher in fatal cases compared with those who survived (10).
	 Plasma levels were significantly higher in Rwandan patients with severe malaria, compared with uncomplicated cases and controls (5).
	 Plasma levels were significantly higher in Colombian patients with <i>vivax</i> severe malaria, compared with uncomplicated cases and healthy controls (6).
	 IL-10 production was only observed in Brazilian patients with <i>vivax</i> malaria, compared with previously exposed, non-infected subjects and unexposed healthy donors. Infected patients presented a moderate correlation between IL-10 and IL-6 plasma levels (13).
	 In Brazilian patients with different forms of <i>vivax</i> malaria and controls, a network analysis revealed a protective role of IL-10 and IL-4 in non-infected and asymptomatic <i>vivax</i> patients (7).
	 In Pakistani patients with <i>vivax</i> malaria, plasma levels were significantly higher in uncomplicated cases than healthy controls, and higher again in complicated cases compared with uncomplicated ones. IL-10, TNF- $\alpha$ , ICAM-1 and VCAM-1 were the best individual predictors of complicated <i>vivax</i> malaria (14).



### Chemokines

Biomarker	Clinical significance in malaria infection
<b>CCL2</b>	 Plasma levels were significantly higher in Colombian patients with <i>vivax</i> severe malaria, compared with uncomplicated cases and healthy controls (6).
	 Plasma levels were significantly increased in Brazilian patients with <i>vivax</i> malaria, compared with previously exposed, uninfected subjects. Infected patients showed a strong correlation between CCL2 and IL-6 plasma levels (13).



<b>CCL4</b>		Plasma levels were significantly higher in Brazilian patients with acute <i>falciparum</i> and <i>vivax</i> malaria, compared with healthy controls. During the convalescent phase, levels were higher in <i>falciparum</i> patients as compared to <i>vivax</i> cases (22).
<b>CCL5</b>		Serum levels were significantly lower in Indian patients with <i>falciparum</i> severe malaria, compared with uncomplicated cases and healthy controls (23).
		Plasma levels were significantly lower in Brazilian patients with <i>vivax</i> malaria, compared with previously exposed, non-infected subjects and unexposed healthy donors (13).
		In Brazilian patients with different forms of <i>vivax</i> malaria and controls, a network analysis revealed that CCL5, IFN- $\gamma$ , and TNF- $\alpha$ were crucial in the profile of mild malaria cases (7).
<b>CCL18</b>		To the best of our knowledge, no studies have reported significant group differences in the context of human malaria.





**Other immune markers**

Biomarker	Description	Clinical significance
<b>OPN</b>	Extracellular matrix bone protein. It can act as a cytokine, enhancing production of IFN- $\gamma$ and IL-12 and reducing production of IL-10.	 Plasma concentrations in Ugandan infants with <i>falciparum</i> malaria were inversely correlated with <i>falciparum</i> -specific atypical memory B cells, suggesting that OPN could have a role in the acquisition of natural immunity against malaria (24).
		 Plasma levels were significantly higher in Singapore patients with vascular cognitive impairment, compared with cognitively normal controls (25).
<b>RAGE</b>	Cell surface pattern recognition receptor. Triggers a pro-inflammatory response.	To the best of our knowledge, no studies have reported significant group differences in the context of human malaria.

**CCL2**: chemokine (C-C motif) ligand 2; **CCL4**: chemokine (C-C motif) ligands 4; **CCL5**: chemokine (C-C motif) ligand 5; **CCL18**: chemokine (C-C motif) ligand 18; **CNS**: central nervous system; **CRP**: C-reactive protein; **CSF**: cerebrospinal fluid; **GM-CSF**: granulocyte-macrophage colony-stimulating factor; **IFN- $\gamma$** : interferon gamma; **IL-1 $\alpha$** : interleukin 1 alpha; **IL-1 $\beta$ \***: interleukin 1 beta; **IL-1RA**: interleukin 1RA; **IL-2**: interleukin 2; **IL-4\*\***: interleukin 4; **IL-6\***: interleukin 6; **IL-8**: interleukin 8; **IL-10**: interleukin 10; **IL-17A**: interleukin 17; **ILC**: innate lymphoid cells; **MIF**: migration inhibitory factor; **MPO**: myeloperoxidase; **NK**: natural killer; **OPN**: osteopontin; **RAGE**: receptor for advanced glycation end-products; **TNF- $\alpha$** : tumour Necrosis Factor alpha; **VSMC**: vascular smooth muscle cells.

\*May have anti-inflammatory functions. \*\*May have pro-inflammatory functions.

**Legend:** Clinical findings related to...

 *Plasmodium falciparum* malaria infection;  *Plasmodium vivax* malaria infection;  *Plasmodium knowlesi* malaria infection;  Neurological conditions.

## References:

1. Villaverde C, Namazzi R, Shabani E, *et al*. Retinopathy-Positive Cerebral Malaria Is Associated With Greater Inflammation, Blood-Brain Barrier Breakdown, and Neuronal Damage Than Retinopathy-Negative Cerebral Malaria. *J Pediatric Infect Dis Soc* (2020) 9(5):580–6.
2. Kho S, Anstey NM, Barber BE, *et al*. Diagnostic performance of a 5-plex malaria immunoassay in regions co-endemic for *Plasmodium falciparum*, *P. vivax*, *P. knowlesi*, *P. malariae* and *P. ovale*. *Scientific Reports* (2022) 12(1):1–9.
3. Peto TJ, Tripura R, Lee SJ, *et al*. Association between Subclinical Malaria Infection and Inflammatory Host Response in a Pre-Elimination Setting. *PLoS One* (2016) 11(7):e0158656.
4. Lima-Junior J da C, Rodrigues-da-Silva RN, Pereira VA, *et al*. Cells and mediators of inflammation (C-reactive protein, nitric oxide, platelets and neutrophils) in the acute and convalescent phases of uncomplicated *Plasmodium vivax* and *Plasmodium falciparum* infection. *Mem Inst Oswaldo Cruz* (2012) 107(8):1035–41.
5. Ndoricympaye EL, Van Snick J, Niyoyita J de D, *et al*. Integrated Analysis of Cytokine Profiles in Malaria Patients Discloses Selective Upregulation of TGF- $\beta$ 1,  $\beta$ 3, and IL-9 in Mild Clinical Presentation. *Int J Mol Sci* (2022) 23(20):12665.
6. Acero CT, Ramírez-Montoya J, Velasco MC, *et al*. IL-4, IL-10, CCL2 and TGF- $\beta$  as potential biomarkers for severity in *Plasmodium vivax* malaria. *PLoS Negl Trop Dis* (2022) 16(9):e0010798.
7. Mendonça VR, Queiroz AT, Lopes FM, *et al*. Networking the host immune response in *Plasmodium vivax* malaria. *Malar J* (2013) 12(1):1–11.
8. Mahittikorn A, Kwankaew P, Rattaprasert P, *et al*. Elevation of serum interleukin-1 $\beta$  levels as a potential indicator for malarial infection and severe malaria: a meta-analysis. *Malar J* (2022) 21(1):1–11.
9. Prakash D, Fesel C, Jain R, *et al*. Clusters of cytokines determine malaria severity in *Plasmodium falciparum*-infected patients from endemic areas of Central India. *J Infect Dis* (2006) 194(2):198–207.
10. Royo J, Vianou B, Accrombessi M, *et al*. Elevated plasma interleukin-8 as a risk factor for mortality in children presenting with cerebral malaria. *Infect Dis Poverty* (2023) 12(1):1–15.
11. Moncunill G, Mayor A, Bardají A, *et al*. Cytokine Profiling in Immigrants with Clinical Malaria after Extended Periods of Interrupted Exposure to *Plasmodium falciparum*. *PLoS One* (2013) 8(8):e73360.
12. Moncunill G, Mayor A, Jiménez A, *et al*. Cytokine and Antibody Responses to *Plasmodium falciparum* in Naïve Individuals during a First Malaria Episode: Effect of Age and Malaria Exposure. *PLoS One* (2013) 8(2):e55756.
13. Hojo-Souza NS, Pereira DB, De Souza FSH, *et al*. On the cytokine/chemokine network during *Plasmodium vivax* malaria: new insights to understand the disease. *Malar J* (2017) 16(1):1–10.
14. Raza A, Ghanchi NK, Zubairi ABS, *et al*. Tumor Necrosis Factor - $\alpha$ , Interleukin-10, Intercellular and Vascular Adhesion Molecules Are Possible Biomarkers of Disease Severity in Complicated *Plasmodium vivax* Isolates from Pakistan. *PLoS One* (2013) 8(12):e81363.
15. Obeng-Aboagye E, Frimpong A, Amponsah JA, *et al*. Inflammatory cytokines as potential biomarkers for early diagnosis of severe malaria in children in Ghana. *Malar J* (2023) 22(1):1–8.
16. Herbert F, Tchitchek N, Bansal D, *et al*. Evidence of IL-17, IP-10, and IL-10 involvement in multiple-organ dysfunction and IL-17 pathway in acute renal failure associated to *Plasmodium falciparum* malaria. *J Transl Med* (2015) 13(1):1–11.
17. Han C, Lin Y, Shan G, *et al*. Plasma concentration of malaria parasite-derived macrophage migration inhibitory factor in uncomplicated malaria patients correlates with parasitemia and disease severity. *Clin Vaccine Immunol* (2010) 17(10):1524–32.
18. Ngum NH, Fakeh NB, Lem AE, *et al*. Prevalence of malaria and associated clinical manifestations and myeloperoxidase amongst populations living in different altitudes of Mezam division, North West Region, Cameroon. *Malar J* (2023) 22(1):1–14.
19. Kinra P, Dutta V. Serum TNF alpha levels: a prognostic marker for assessment of severity of malaria. *Trop Biomed* (2013) 30(4):645–53.
20. Mandala WL, Msefula CL, Gondwe EN, *et al*. Monocyte activation and cytokine production in Malawian children presenting with *P. falciparum* malaria. *Parasite Immunol* (2016) 38(5):317–25.
21. Cox-Singh J, Singh B, Daneshvar C, *et al*. Anti-Inflammatory Cytokines Predominate in Acute Human *Plasmodium knowlesi* Infections. *PLoS One* (2011) 6(6):e20541.
22. Rodrigues da Silva RN, Lima Junior J da C, Fonseca e Fonseca B de P, *et al*. Alterations in cytokines and haematological parameters during the acute and convalescent phases of *Plasmodium falciparum* and *Plasmodium vivax* infections. *Mem Inst Oswaldo Cruz* (2014) 109(2):154–62.
23. Bujarbaruah D, Kalita MP, Baruah V, *et al*. RANTES levels as a determinant of *falciparum* malaria severity or recovery. *Parasite Immunol* (2017) 39(9):e12452.
24. Mortazavi SE, Lugaajju A, Kaddumukasa M, *et al*. Osteopontin and malaria: no direct effect on parasite growth, but correlation with *P. falciparum*-specific B cells and BAFF in a malaria endemic area. *BMC Microbiol* (2021) 21(1):1–13.
25. Chai YL, Chong JR, Raquib AR, *et al*. Plasma osteopontin as a biomarker of Alzheimer's disease and vascular cognitive impairment. *Sci Rep* (2021) 11(1):1–11.